



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CCT128930

Cat. No.:	HY-13260
CAS No.:	885499-61-6
Molecular Formula:	C ₁₈ H ₂₀ ClN ₅
Molecular Weight:	341.84
Target:	Akt; Autophagy; Apoptosis
Pathway:	PI3K/Akt/mTOR; Autophagy; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (97.50 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.9253 mL	14.6267 mL	29.2535 mL
		5 mM		0.5851 mL	2.9253 mL	5.8507 mL
		10 mM		0.2925 mL	1.4627 mL	2.9253 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC ₅₀ =6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC ₅₀ =168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC ₅₀ =120 nM). Antitumor activity.			
IC ₅₀ & Target	Akt2 6 nM (IC ₅₀)	p70S6K 120 nM (IC ₅₀)	PKA 168 nM (IC ₅₀)	Autophagy
	Apoptosis			

In Vitro	The GI₅₀ values of CCT128930 for growth inhibition are 6.3 μM for U87MG human glioblastoma cells, 0.35 μM for LNCaP human prostate cancer cells, and 1.9 μM for PC3 human prostate cancer cells, all of which are PTEN-deficient human tumor cell lines^[1]. CCT128930 (0.1-60 μM; 1 hour; U87MG human glioblastoma cells) shows an initial induction of AKT phosphorylation at serine 473 up to 20 μM, followed by a decreased in phosphorylation at higher concentrations^[1]. CCT128930 inhibits direct substrates of AKT (Ser9 GSK3β, pThr246 PRAS40 and pT24 FOXO1/p32 FOXO3a) at ≥5 μM, and the downstream target, pSer235/236 S6RP at ≥ 10 μM, with generally constant levels of the respective total proteins and GAPDH ^[1]. CCT128930 (18.9 μM; U87MG human glioblastoma cells) causes an increase in phosphorylation of pSer473 AKT after 30 minutes, which is sustained for 48 hours. Total AKT protein signal decreases gradually from 8 hours to 48 hours of treatment ^[1]. CCT128930 (PTEN-null U87MG human glioblastoma cells; over a 24-hour time period) results in an increase in G0/G1 phase cells from 43.6% to 64.8% after 24 hours of treatment^[1]. CCT128930 (0-10 μM; 24 hours) increases, but not inhibites, the phosphorylation of Akt in HepG2 and A549 cells. CCT128930 (0-20 μM; 24 hours) inhibits cell proliferation by inducing cell cycle arrest in G1 phase through downregulation of cyclinD1 and Cdc25A, and upregulation of p21, p27 and p53. CCT128930 (20 μM) triggers cell apoptosis with activation of caspase-3, caspase-9, and PARP. CCT128930 (0-20 μM; 24 hours) increases phosphorylation of ERK and JNK in HepG2 cells. CCT128930 (0-20 μM; 24 hours) activates DNA damage response of HepG2 cell characterized by phosphorylation of H2AX, ATM (ataxia-telangiectasia mutated), Chk1 and Chk2^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.																																																					
In Vivo	CCT128930 (25 or 40 mg/kg; i.p. daily or twice daily for 5 days) shows antitumor activities in U87MG and BT474 human breast cancer xenografts^[1]. Summary of the pharmacokinetic parameters of CCT128930 (25 mg/kg) in CrTacNCR-Fox1nu mice^[1] <table><tr><th>Tissue</th><th>Route</th><th>T_{1/2} (h)</th><th>T_{max} (h)</th><th>C_{max} (μM)</th><th>V_{ss} (L)</th><th>Cl (L/h)</th><th>AUC_{0-∞} (μMh)</th><th>Bioavailability (%)</th></tr><tr><td>Plasma</td><td>i.v.</td><td>0.95</td><td>0.083</td><td>6.36</td><td>0.25</td><td>0.325</td><td>4.62</td><td>100</td></tr><tr><td>Plasma</td><td>i.p.</td><td>2.33</td><td>0.5</td><td>1.28</td><td>N/A</td><td>0.372</td><td>1.33</td><td>28.8</td></tr><tr><td>Tumor</td><td>i.p.</td><td>3.89</td><td>1</td><td>8.02</td><td>N/A</td><td>0.06[*]</td><td>25.8</td><td>N/A</td></tr><tr><td>Plasma</td><td>p.o.</td><td>0.57</td><td>0.5</td><td>0.432</td><td>N/A</td><td>0.317</td><td>0.392</td><td>8.5</td></tr></table> [*]Apparent clearance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>6-8 weeks old female CrTacNCR-Fox1nu mice^[1]</td></tr><tr><td>Dosage:</td><td>25 mg/kg (U87MG human glioblastoma xenografts) or 40 mg/kg (BT474 human breast cancer xenografts)</td></tr><tr><td>Administration:</td><td>i.p. daily for 5 days (U87MG human glioblastoma xenografts); i.p. twice daily for 5 days (BT474 human breast cancer xenografts)</td></tr><tr><td>Result:</td><td>Giving a treated:control (T/C) ratio on day 12 of 48%. There was no weight loss associated with this regime in U87MG human glioblastoma xenografts. Had a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. This regimen was associated with minimal weight loss, with a nadir of only 94.8%</td></tr></table>	Tissue	Route	T _{1/2} (h)	T _{max} (h)	C _{max} (μM)	V _{ss} (L)	Cl (L/h)	AUC _{0-∞} (μMh)	Bioavailability (%)	Plasma	i.v.	0.95	0.083	6.36	0.25	0.325	4.62	100	Plasma	i.p.	2.33	0.5	1.28	N/A	0.372	1.33	28.8	Tumor	i.p.	3.89	1	8.02	N/A	0.06 [*]	25.8	N/A	Plasma	p.o.	0.57	0.5	0.432	N/A	0.317	0.392	8.5	Animal Model:	6-8 weeks old female CrTacNCR-Fox1nu mice ^[1]	Dosage:	25 mg/kg (U87MG human glioblastoma xenografts) or 40 mg/kg (BT474 human breast cancer xenografts)	Administration:	i.p. daily for 5 days (U87MG human glioblastoma xenografts); i.p. twice daily for 5 days (BT474 human breast cancer xenografts)	Result:	Giving a treated:control (T/C) ratio on day 12 of 48%. There was no weight loss associated with this regime in U87MG human glioblastoma xenografts. Had a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. This regimen was associated with minimal weight loss, with a nadir of only 94.8%
Tissue	Route	T _{1/2} (h)	T _{max} (h)	C _{max} (μM)	V _{ss} (L)	Cl (L/h)	AUC _{0-∞} (μMh)	Bioavailability (%)																																														
Plasma	i.v.	0.95	0.083	6.36	0.25	0.325	4.62	100																																														
Plasma	i.p.	2.33	0.5	1.28	N/A	0.372	1.33	28.8																																														
Tumor	i.p.	3.89	1	8.02	N/A	0.06 [*]	25.8	N/A																																														
Plasma	p.o.	0.57	0.5	0.432	N/A	0.317	0.392	8.5																																														
Animal Model:	6-8 weeks old female CrTacNCR-Fox1nu mice ^[1]																																																					
Dosage:	25 mg/kg (U87MG human glioblastoma xenografts) or 40 mg/kg (BT474 human breast cancer xenografts)																																																					
Administration:	i.p. daily for 5 days (U87MG human glioblastoma xenografts); i.p. twice daily for 5 days (BT474 human breast cancer xenografts)																																																					
Result:	Giving a treated:control (T/C) ratio on day 12 of 48%. There was no weight loss associated with this regime in U87MG human glioblastoma xenografts. Had a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. This regimen was associated with minimal weight loss, with a nadir of only 94.8%																																																					

of the initial body weight on day 15 of treatment in BT474 human breast cancer xenografts.

CUSTOMER VALIDATION

- Biochem Biophys Res Commun. 2021 May 11;560:132-138.
- J Healthc Eng. 05 Jan 2022.
- Oncotarget. 2016 May 17;7(20):29131-42.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Yap TA et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011 Feb;10(2):360-71.
- [2]. Wang FZ, et al. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. Biochimie. 2014;103:118-125.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA